Skip to main content
Fig. 6 | Diabetology & Metabolic Syndrome

Fig. 6

From: Insight into the hepatoprotective, hypolipidemic, and antidiabetic impacts of aliskiren in streptozotocin-induced diabetic liver disease in mice

Fig. 6

Effect of one month treatment with aliskiren on Microscopic examination of different hepatic tissue sections in STZ-induced diabetes in mice (H and E-stained) (× 400). a: normal control, b: diabetic control and c: aliskiren treated group. a Normal controls demonstrated normal morphological features of hepatic parenchyma with many apparent intact hepatocytes having large vesicular nuclei, intact hepatic vasculatures were observed with minimal degenerative changes. b Diabetic model samples showed significant periportal and perivascular inflammatory cells infiltrates with mild vacuolar degenerative changes of hepatocytes with many nucleocytomegaly records with prominent nucleoli. c Aliskiren treated group showed minimal inflammatory cells infiltrates records with more apparent intact hepatocytes with occasional nucleocytomegaly and or binucleation alternated with fewer degenerated cells accompanied with activated kupffer cells

Back to article page